TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27143353
Drug: Leptin antagonist
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin antagonist applied locally to the ascending aorta in AngII-infused mice.
Study: 27145310
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (nonantibiotic) consisting of mild analgesics (nonsteroidal anti-inflammatory drug or paracetamol)
Study: 27145310
Drug: Symptomatic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic treatment (nonantibiotic)
Study: 27146701
Drug: Implants (10,096
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implants (10,096 total)
Study: 27146701
Drug: Antidepressants intake
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants intake
Study: 27146799
Drug: Exenatide Once
Normalized name: Exenatide
DrugBank: Exenatide (DB01276)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exenatide Once Weekly (QW)
Study: 27148452
Drug: CC-486 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 (300 mg once daily for the first 21 days of 28-day treatment cycles)
Study: 27148452
Drug: Placebo (once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (once daily for the first 21 days of 28-day treatment cycles)
Study: 27149114
Drug: PPV23 (23-valent
Approvals — FDA: no, EMA: no, PMDA: no
Description: PPV23 (23-valent pneumococcal polysaccharide vaccine) administered intramuscularly as a single dose
Study: 27150464
Drug: Valproic acid
Normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproic acid (VPA) or treatment as usual (TAU)
Study: 27150686
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (H2RAs) used by 313 participants
Study: 27150686
Drug: H2 receptor
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 receptor antagonists (H2RAs)
Study: 27150686
Drug: Non-use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-use of H2 receptor antagonists (H2RAs)
Study: 27151914
Drug: Cell-assisted lipotransfer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell-assisted lipotransfer using freshly isolated autologous adipose-derived stromal cells (4.07 × 10(7) cells with 10 ml of lipoaspirate)
Study: 27151994
Drug: Entinostat (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (10 or 15 mg oral entinostat once every other week)
Study: 27151994
Drug: Entinostat (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entinostat (15 mg oral entinostat once weekly in 3 of 4 weeks)
Study: 27152857
Drug: Chemotherapy during
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy during radiation for PET nonresponders who changed chemotherapy (38 patients)
Study: 27152857
Drug: Chemotherapy during
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy during radiation for PET responders (113 patients)
Study: 27152857
Drug: Chemotherapy during
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy during radiation for PET nonresponders who did not change chemotherapy (50 patients)
Study: 27152857
Drug: PET nonresponders
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET nonresponders who did not change chemotherapy (50 patients)
Study: 27152857
Drug: PET nonresponders
Normalized name: Pet Pectillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET nonresponders who changed chemotherapy (38 patients)
Study: 27153246
Drug: faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: faldaprevir 120 mg q.d. for 12 or 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Study: 27153246
Drug: faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: faldaprevir 240 mg q.d. for 12 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Study: 27153246
Drug: faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 24 or 48 weeks
Study: 27153246
Drug: faldaprevir 240
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: faldaprevir 240 mg q.d. for 24 weeks plus PegIFNα-2b/RBV for 48 weeks
Study: 27153246
Drug: faldaprevir 120
Normalized name: Faldaprévir
DrugBank: Faldaprevir (DB11808)
Approvals — FDA: no, EMA: no, PMDA: no
Description: faldaprevir 120 mg q.d. plus PegIFNα-2b/RBV
Study: 27153752
Drug: EHR patient
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EHR patient portal message promoting influenza vaccines and offering online appointment scheduling
Study: 27154719
Drug: Activated protein
Normalized name: Activated protein C
DrugBank: Drotrecogin alfa (DB00055)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated protein C (DAA) 24 mg/kg/h for 96 h
Study: 27154719
Drug: Hydrocortisone 50
Normalized name: hydrocortisone 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrocortisone 50 mg intravenous bolus q6 for 7 days
Study: 27154719
Drug: Fludrocortisone 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fludrocortisone 50 µg once daily for 7 days
Study: 27154719
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of DAA and corticosteroids
Study: 27156227
Drug: Onalespib (AT13387)
Normalized name: Onalespib
DrugBank: Onalespib (DB06306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onalespib (AT13387) 150-220 mg/m² once-weekly intravenous for 3 weeks and imatinib 400 mg daily
Study: 27157491
Drug: Pembrolizumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (10 mg/kg intravenously every 2 weeks for 24 months)
Study: 27158544
Drug: PEG 3350
Normalized name: PEG 3350
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PEG 3350 17 g once daily for 7 days
Study: 27165786
Drug: Mecillinam (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mecillinam (400 mg pivmecillinam hydrochloride three times a day for 7 days)
Study: 27167058
Drug: Intraoperative fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative fluid challenge with 10 ml/kg of 0.9% normal saline
Study: 27167209
Drug: Oral macrolides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral macrolides after an initial 4-week IV amikacin and cefoxitin (or imipenem) treatment
Study: 27167209
Drug: Oral macrolides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral macrolides after an initial 2-week IV amikacin and cefoxitin (or imipenem) treatment
Study: 27169385
Drug: Evofosfamide (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide (Arm A) - 30-60 min/day infusion on Days 1-5 of a 21-day cycle
Study: 27169385
Drug: Evofosfamide (Arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evofosfamide (Arm B) - Continuous infusion over 120 hr on Days 1-5 of a 21-day cycle
Study: 27169478
Drug: Isavuconazole (ISAV)
Normalized name: isavuconazole
DrugBank: Isavuconazole (DB11633)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (ISAV) 200 mg 3 times daily for 2 days followed by 200 mg once-daily (IV or PO)
Study: 27169571
Drug: Complementary/integrative medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary/integrative medicine (CIM) treatment
Study: 27169792
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg everolimus once daily
Study: 27169903
Drug: Cenicriviroc 150
Normalized name: Cénicriviroc
DrugBank: Cenicriviroc (DB11758)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cenicriviroc 150 mg once daily for 14 days
Study: 27171984
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy with vincristine, prednisone, doxorubicin, and pegylated asparaginase; Imatinib for Philadelphia chromosome-positive disease; followed by consolidation with clofarabine.
Study: 27172991
Drug: Sloped shoulder
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sloped shoulder configuration implants
Study: 27174159
Drug: Other oral
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other oral continuous combined HRT (HRTcc)
Study: 27175116
Drug: Adalimumab 160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 160/80 mg
Study: 27175116
Drug: Adalimumab 80/40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 80/40 mg
Study: 27175291
Drug: EASY model
Normalized name: Easy Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: EASY model (group-based education, individualized physical activity prescription, Fitbit monitor)
Study: 27175296
Drug: tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tofacitinib 5 or 10 mg twice daily
Study: 27175296
Drug: MTX titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX titrated to 20 mg/week
Study: 27175553
Drug: Serum 25-hydroxyvitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum 25-hydroxyvitamin D concentration (mean total 25-OHD concentration 32.2 nmol/l, range 21.8-46.6 nmol/l)
Study: 27175553
Drug: Insulin sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin sensitivity assessment using two-step euglycaemic hyperinsulinaemic clamp and HOMA2-IR
Study: 27177028
Drug: Central augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Central augmentation index (AIx_75)
Study: 27177177
Drug: Trans sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans sodium crocetinate (TSC) with radiation therapy (RT) and temozolomide (TMZ)
Study: 27178240
Drug: Venetoclax monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venetoclax monotherapy (20, 50, 100, 200, 400 mg ramp-up to 400 mg daily)
Study: 27178765
Drug: Methadone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone treatment program (MTP)
Study: 27179604
Drug: Asthma treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asthma treatment (specifics not provided)
Study: 27180047
Drug: SMART study
Normalized name: benzalkonium chloride Topical Foam [Smart San]
Approvals — FDA: no, EMA: no, PMDA: no
Description: SMART study of antipsychotic medications
Study: 27181924
Drug: IVF treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVF treatments
Study: 27185573
Drug: Dalotuzumab monotherapy
Normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalotuzumab monotherapy at 900 mg/m2
Study: 27185573
Drug: Dalotuzumab monotherapy
Normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalotuzumab monotherapy at 1200 mg/m2
Study: 27185573
Drug: Dalotuzumab monotherapy
Normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalotuzumab monotherapy at 1500 mg/m2
Study: 27185573
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of dalotuzumab and ridaforolimus (28 mg/m2 daily for days 1-5, repeated weekly)
Study: 27185573
Drug: Dalotuzumab monotherapy
Normalized name: dalotuzumab
DrugBank: Dalotuzumab (DB11840)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dalotuzumab monotherapy
Study: 27185799
Drug: Isavuconazole (Cresemba);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (Cresemba); pharmacokinetic analysis based on a 2-compartment model with first-order absorption.
Study: 27185799
Drug: Isavuconazole (Cresemba);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isavuconazole (Cresemba); impact of covariates on pharmacokinetics.
Study: 27185808
Drug: Tedizolid phosphate
Normalized name: Tedizolid Phosphate
DrugBank: Tedizolid (DB14569)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tedizolid phosphate (single intravenous dose)
Study: 27188262
Drug: Conventional dietary
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional dietary treatment (CDT)
Study: 27188804
Drug: Miltefosine (MF)
Normalized name: Miltefosine
DrugBank: Miltefosine (DB09031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miltefosine (MF) for 12 weeks at an allometric dose
Study: 27189815
Drug: NT-proBNP (≥1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP (≥1,600 pg/ml)
Study: 27190628
Drug: Concurrent PET-CT
Normalized name: Pet-ema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent PET-CT imaging
Study: 27190628
Drug: T-cell therapy
Normalized name: Anti-CD5 CAR T-cell therapy
DrugBank: Anti-CD5 CAR T-cell therapy (DB17279)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell therapy
Study: 27192671
Drug: Danazol 800
Normalized name: Danazol
DrugBank: Danazol (DB01406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Danazol 800 mg per day for 24 months
Study: 27195129
Drug: Second-generation capsule
Normalized name: regenerated cellulose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Second-generation capsule colonoscopy (CC2)
Study: 27195129
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate as a boost agent
Study: 27196589
Drug: Split-dose uptake
Normalized name: influenza A virus (H1N1) antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Split-dose uptake based on appointment time
Study: 27197177
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy (N = 122/188, 65%)
Study: 27197177
Drug: Unmatched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unmatched therapy (N = 66/188, 35%)
Study: 27198664
Drug: Ledipasvir/Sofosbuvir fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir/Sofosbuvir fixed-dose combination tablet for 12 weeks
Study: 27199429
Drug: 3BNC117 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3BNC117 infusion
Study: 27199889
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment with five consecutive days of 2 mA cathodal tDCS over M1 for 20 min
Study: 27199889
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment plus sham tDCS
Study: 27206575
Drug: Telmisartan 80
Normalized name: telmisartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan 80 mg for 7 days followed by chlorthalidone 25 mg for 14 days (coadministered from day 15).
Study: 27206575
Drug: Chlorthalidone 25
Normalized name: chlorthalidone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 25 mg for 13 days followed by coadministration with telmisartan 80 mg for 7 days.
Study: 27206943
Drug: ETC-1002 120
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 120 mg plus EZE
Study: 27206943
Drug: ETC-1002 180
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ETC-1002 180 mg plus EZE
Study: 27207512
Drug: Type 1
Normalized name: Type 1 H substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type 1 diabetes patients with PPARG G allele
Study: 27207788
Drug: Carfilzomib 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib 70 mg/m(2) with dexamethasone (40 mg) on days 1, 8, 15, and 22; dexamethasone omitted on day 22 for cycles 9+.
Study: 27208903
Drug: TAS-102 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAS-102 at 35 mg/m² b.i.d.
Study: 27209012
Drug: Etanercept 50
Normalized name: etanercept 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept 50 mg once weekly plus methotrexate for 36 weeks
Study: 27211104
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α)
Study: 27211503
Drug: Magnetically Controlled
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetically Controlled Capsule Endoscopy (MCE)
Study: 27211612
Drug: Intrathecal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal recombinant human heparan-N-sulfatase (rhHNS) 10, 45, or 90mg via IDDD once monthly for a total of 6 doses
Study: 27212697
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI) therapy after chemotherapy (CT cohort)
Study: 27212697
Drug: Aromatase inhibitors
Normalized name: Aromatase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatase inhibitors (AI) therapy as adjuvant therapy (HT cohort)
Study: 27213629
Drug: Lipoprotein(a) apheresis
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipoprotein(a) apheresis (specific immunosorbent to Lp(a)), removed weekly for 18 months.
Study: 27215497
Drug: Daily inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily inhaled corticosteroid (≥500 μg of fluticasone propionate or equivalent) and at least 1 second controller medication
Study: 27215497
Drug: Data collection
Normalized name: NO DATA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Data collection on medication use, asthma exacerbation data, asthma-related healthcare utilization and events raising safety concerns
Study: 27216760
Drug: Seasonal trivalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seasonal trivalent inactivated influenza vaccines (TIIVs)
Study: 27217543
Drug: Molecularly targeted
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecularly targeted therapies (MTT)
Study: 27222473
Drug: Ofatumumab and
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ofatumumab and bendamustine combination
Study: 27226434
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone 40 mg (20 mg for patients aged >75 years)
Study: 27226434
Drug: Pomalidomide 4
Normalized name: pomalidomide 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomalidomide 4 mg plus low-dose dexamethasone
Study: 27232360
Drug: Open-label ketamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open-label ketamine infusions (0.5 mg/kg over 45 minutes for the first 3 infusions; 0.75 mg/kg over 45 minutes for the last 3)
Study: 27232579
Drug: Simtuzumab 700
Normalized name: Gemtuzumab Ozogamicin
DrugBank: Gemtuzumab ozogamicin (DB00056)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Simtuzumab 700 mg intravenously every 2 weeks for 22 weeks
Study: 27233802
Drug: Moderate CYP3A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate CYP3A inhibitors
Study: 27233802
Drug: Strong CYP3A
Normalized name: Strongid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Strong CYP3A inhibitors
Study: 27233802
Drug: Mild and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mild and moderate renal and hepatic impairment, body weight, age, race, weak CYP3A inhibitors and inducers, OATP1B1 transporter phenotype, P-gp, BCRP, and OATP1B1/OATP1B3 modulators
Study: 27234509
Drug: (99m)Tc-PulmoBind injection
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc-PulmoBind injection for SPECT imaging in humans
Study: 27234509
Drug: (99m)Tc-PulmoBind injection
Normalized name: TC-6987
DrugBank: TC-6987 (DB14854)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (99m)Tc-PulmoBind injection for SPECT imaging in supine dogs (n=5)
Study: 27234642
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor everolimus
Study: 27236150
Drug: Telaprevir-based triple
Normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Telaprevir-based triple therapy (telaprevir 750 mg 8-hourly, pegylated interferon 180 µg weekly, ribavirin 600 mg daily) followed by pegylated interferon and ribavirin alone for 36 weeks.
Study: 27236390
Drug: Tocilizumab (TCZ)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tocilizumab (TCZ) monotherapy or in combination with non-biologic DMARDs, 8 mg/kg infused over 60 minutes every 4 weeks (up to 6 times)
Study: 27237429
Drug: Sofosbuvir (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sofosbuvir (400 mg, once daily) plus ribavirin (1000-1200 mg/day) for 12 weeks
Study: 27238065
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training + stimulant medication + placebo (Basic)
Study: 27238065
Drug: Parent training
Normalized name: C.I. direct red 28 parent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parent training + stimulant + risperidone (Augmented)
Study: 27239329
Drug: budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide MMX 9 mg daily for ≤8 weeks (induction of remission)
Study: 27239329
Drug: budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide MMX added to mesalazine >2 weeks after increased/optimised mesalazine dose (late add-on)
Study: 27239329
Drug: budesonide MMX
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: budesonide MMX as monotherapy (mono)
Study: 27242930
Drug: Cognitive Behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioural Therapy for Insomnia (CBT-i)
Study: 27243356
Drug: Hydrogel daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel daily disposable contact lenses (1-DAY ACUVUE MOIST)
Study: 29098288
Drug: Hypoglossal nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglossal nerve stimulator therapy
Study: 27244882
Drug: nab-paclitaxel (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: nab-paclitaxel (100 mg/m2) on day 1, 8, 22 and 29, and cisplatin (75 mg/m2) on day 1 and 22
Study: 27245095
Drug: Panobinostat (HDAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Panobinostat (HDAC inhibitor)
Study: 27245295
Drug: Maternal Antiretroviral
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal Antiretroviral Therapy (ART)